Aussie mRNA manufacturer 2b DECIDED this week, page-30

i agree. I see IDT as a good long hold no matter what transpires in the short term. It appears to have nice steady leadership, keeps its nose clean, not laden with debt, doesnt beg for attention and its resilient. For a small company to have survived for such an extended period, in a challenging industry shows it has stamina.
What ever the short term outcome, it will have a greater profit than last year.
If it was another entity, with different leadership it would have likely taken on considerable debt and engaged in capital raising before an announcement ("jumped the gun"). Another quality I see in the company is, it does what it says. There is little evidence over the past two years that does not deliver, they just take there time. A measured approach, strategic approach.
I like they do not waste money on superfluous activities (comms teams etc) that are not the core business.